Articles from ShangBay Capital

ShangBay Capital, a prominent venture capital firm specializing in healthcare investments, proudly announces the inclusion of William Dai in GrowthCap's esteemed list of top healthcare investors for 2025.

ShangBay Capital, a prominent venture capital firm specializing in healthcare investments, proudly announces the inclusion of William Dai in GrowthCap's esteemed list of top healthcare investors for 2024.

ShangBay Capital, a venture capital firm focused on investing in healthcare companies, is proud to announce that William Dai has been selected by GrowthCap for his contributions as one of the top investors in healthcare among an impressive list of awardees.

ShangBay Capital, a venture capital firm focused on investing in early-stage healthcare companies, today announced that Robert Kamen, Ph.D., has joined its advisory team as a Senior Advisor. The venture capital firm is one of the most prolific investors in medtech. Dr. Kamen will provide tremendous value in the biotech and biopharma investment fields for potential new companies.

ShangBay Capital today announced Dr. Malcolm Munro and Michael Wallace have joined as Senior Advisors to its advisory team after the first closing of its third fund. The venture capital firm is one of the most prolific investors in medtech. Fund III, the largest fund to date, will invest in early-stage and growth stage companies addressing the most pressing challenges facing patients today.